Compare Marathon Petroleum Corp (MPC) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marathon Petroleum Corp vs GeneDx Holdings Corp — how do they compare? Marathon Petroleum Corp trades at $461.46 (market cap $130.12B), while GeneDx Holdings Corp trades at $67.6 (market cap $2.02B). The key difference: Marathon Petroleum Corp is far larger — about 64.4× GeneDx Holdings Corp's market cap, and Marathon Petroleum Corp pays a 0.86% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Marathon Petroleum Corp for 54 Days and GeneDx Holdings Corp for 19 Days on average.
| MPC | WGS | |
|---|---|---|
Market Cap | $130.12B | $2.02B |
Volume | 2,749,647 | 734,640 |
Sector | Energy | Health |
52-Week High | $463.34 | $167.51 |
52-Week Low | $162.63 | $34.51 |
Typical Hold Time | 54 Days | 19 Days |
Enterprise Value | $156.64B | $2.05B |
Dividend Yield | 0.86% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marathon Petroleum (MPC) trades at $442.26, up 2.29% with strong technical momentum and bullish moving average signals. The stock shows robust fundamentals with a P/E of 15.33, ROE of 47.9%, and consistent earnings beats in recent quarters. Recent news highlights refining margin strength amid tight global capacity, though potential diesel export restrictions pose headwinds. Technical indicators show the stock trading near pivot point resistance at $442 with RSI suggesting potential overbought conditions.
MPC presents a compelling value opportunity with attractive valuation metrics and strong profitability, though investors face risks from potential regulatory changes and volatile energy markets. Analyst consensus remains strongly bullish with 76% buy ratings and a $420.30 price target, suggesting modest downside from current levels. The company's solid cash flow generation and dividend payments provide shareholder returns support.
GeneDx (WGS) trades at $68.53, down 4.18% today amid bearish technical signals despite recent positive earnings surprises. The stock shows mixed fundamentals with strong revenue growth to $454M in 2026 but negative profitability metrics including -23.4% net margin. Recent developments include new genomic testing products and hospital partnerships, while analyst consensus remains strongly bullish with a $81 price target representing 18% upside potential.
The investment case balances strong analyst support and genomic testing market growth against persistent profitability challenges and negative cash flow trends. Key catalysts include Q3 2026 earnings due soon and continued execution on operational improvements, while risks center on margin recovery timeline and competitive pressures in the rapidly evolving genomics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marathon Petroleum Corp
Marathon Petroleum is an independent refiner with 13 refineries in the midcontinent, West Coast, and Gulf Coast of the United States with total throughput capacity of 2.9 million barrels per day. Its Dickinson, ND, facility produces 184 million gallons a year of renewable diesel. Its Martinez, CA, facility will have the ability to produce 730 million gallons a year of renewable diesel once converted. The firm also owns and operates midstream assets primarily through its listed MLP, MPLX.
Read more on MPC →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
